Marksans Pharma Limited (MARKSANS.BO)
INR 314.2
(-2.1%)
INR 314.2
(-2.1%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.95 Billion INR | 39.91% |
| 2022 | 4.25 Billion INR | 1.96% |
| 2021 | 4.17 Billion INR | 28.96% |
| 2020 | 3.23 Billion INR | 27.58% |
| 2019 | 2.53 Billion INR | 1.01% |
| 2018 | 2.51 Billion INR | -0.3% |
| 2017 | 2.51 Billion INR | -19.34% |
| 2016 | 3.12 Billion INR | 17.01% |
| 2015 | 2.66 Billion INR | -7.28% |
| 2014 | 2.87 Billion INR | -15.7% |
| 2013 | 3.41 Billion INR | 10.89% |
| 2012 | 3.07 Billion INR | -43.79% |
| 2011 | 5.47 Billion INR | -1.26% |
| 2010 | 5.54 Billion INR | 14.67% |
| 2009 | 4.83 Billion INR | 1.03% |
| 2008 | 4.78 Billion INR | 16.98% |
| 2007 | 4.09 Billion INR | 12.41% |
| 2006 | 3.64 Billion INR | 4.82% |
| 2005 | 3.47 Billion INR | 161.74% |
| 2004 | 1.32 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -20.85 Billion INR | -450.54% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 4.16 Billion INR | 0.0% |
| 2023 FY | 5.95 Billion INR | 39.91% |
| 2023 Q4 | 5.95 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 4.25 Billion INR | 0.0% |
| 2022 FY | 4.25 Billion INR | 1.96% |
| 2022 Q2 | 3.85 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q4 | 4.17 Billion INR | 0.0% |
| 2021 Q2 | 2.91 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 4.17 Billion INR | 28.96% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 2.98 Billion INR | 0.0% |
| 2020 Q4 | 3.23 Billion INR | 0.0% |
| 2020 FY | 3.23 Billion INR | 27.58% |
| 2019 FY | 2.53 Billion INR | 1.01% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 2.09 Billion INR | 0.0% |
| 2019 Q4 | 2.53 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 2.51 Billion INR | -0.3% |
| 2018 Q2 | 2.4 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 2.51 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 2.51 Billion INR | -19.34% |
| 2017 Q4 | 2.51 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 3.79 Billion INR | 0.0% |
| 2016 FY | 3.12 Billion INR | 17.01% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 2.37 Billion INR | 0.0% |
| 2016 Q4 | 3.12 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q4 | 2.66 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 2.79 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 2.66 Billion INR | -7.28% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 2.87 Billion INR | -8.37% |
| 2014 Q3 | 3.13 Billion INR | -0.75% |
| 2014 Q2 | 3.16 Billion INR | 0.0% |
| 2014 FY | 2.87 Billion INR | -15.7% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 3.18 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 3.41 Billion INR | 0.0% |
| 2013 FY | 3.41 Billion INR | 10.89% |
| 2012 FY | 3.07 Billion INR | -43.79% |
| 2012 Q2 | 11.55 Billion INR | 0.0% |
| 2012 Q4 | 3.07 Billion INR | 0.0% |
| 2011 FY | 5.47 Billion INR | -1.26% |
| 2010 FY | 5.54 Billion INR | 14.67% |
| 2009 FY | 4.83 Billion INR | 1.03% |
| 2008 FY | 4.78 Billion INR | 16.98% |
| 2007 FY | 4.09 Billion INR | 12.41% |
| 2006 FY | 3.64 Billion INR | 4.82% |
| 2005 FY | 3.47 Billion INR | 161.74% |
| 2004 FY | 1.32 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Abbott India Limited | 14.94 Billion INR | 60.187% |
| Cipla Limited | 59.15 Billion INR | 89.941% |
| Gland Pharma Limited | 19.37 Billion INR | 69.286% |
| GlaxoSmithKline Pharmaceuticals Limited | 17.96 Billion INR | 66.87% |
| Kopran Limited | 2.52 Billion INR | -136.129% |
| NGL Fine-Chem Limited | 929.03 Million INR | -540.497% |
| Pfizer Limited | 6.33 Billion INR | 6.031% |
| Sanofi India Limited | 6.99 Billion INR | 14.945% |
| SMS Pharmaceuticals Limited | 4.97 Billion INR | -19.544% |